Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy
- 1 August 2001
- Vol. 120 (2) , 423-430
- https://doi.org/10.1378/chest.120.2.423
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle CellsJournal of Biological Chemistry, 1999
- A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonistJournal of Allergy and Clinical Immunology, 1998
- The complementary role of glucocorticosteroids and long‐acting β‐adrenergic agonistsAllergy, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Leukotrienes as a Target in Asthma TherapyDrugs, 1994
- Frontiers in medicine: New aspects of asthmaJournal of Internal Medicine, 1992
- Some Methods for Strengthening the Common χ 2 TestsPublished by JSTOR ,1954